Matinas BioPharma to Participate in Annual Piper Sandler Healthcare Conference
November 19 2020 - 4:15PM
Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a
clinical-stage biopharmaceutical company focused on developing next
generation therapeutics to advance standards of care in areas of
significant unmet medical need, has been invited to participate in
a fireside chat as part of the Piper Sandler 32nd Annual Virtual
Healthcare Conference, being held December 1-3, 2020. The Company
will also host investor meetings during the conference.
The pre-recorded fireside chat will be available
on the IR Calendar page of the Investors section of the
Company’s website (www.matinasbiopharma.com) beginning November 23,
2020. A webcast replay will be accessible for 90 days following the
event.About Matinas BioPharma
Matinas BioPharma is a clinical-stage
biopharmaceutical company focused on developing next generation
therapeutics to advance standards of care for patients in areas of
significant unmet medical need. Company leadership has a deep
history and knowledge of drug development and is supported by a
world-class team of scientific advisors.
MAT9001, the Company’s lead product candidate
for the treatment of cardiovascular and metabolic conditions, is a
prescription-only omega-3 fatty acid-based composition, comprised
primarily of EPA and DPA, under development for
hypertriglyceridemia. MAT9001 is currently in a second head-to-head
comparative study against Vascepa® (ENHANCE-IT), with topline data
expected in the first quarter of 2021.
In addition, Matinas is developing a portfolio
of products based upon its proprietary lipid nano-crystal (LNC)
drug delivery platform, which can solve complex challenges relating
to the safe and effective delivery of potent medicines, making them
more targeted, less toxic and orally bioavailable.
MAT2203, the Company’s lead product candidate
utilizing its LNC platform, is an oral, encochleated formulation of
the well-known, but highly toxic, antifungal medicine amphotericin
B, to treat serious invasive fungal infections. MAT2203 is
currently in a Phase 2 open-label, sequential cohort study (EnACT)
in HIV-infected patients with cryptococcal meningitis. EnACT is set
to begin enrolling patients in its second cohort, with the next
DSMB evaluation of safety and efficacy data anticipated to occur in
the middle of 2021.
Forward Looking Statements
This release contains "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995, including those relating to the Company’s
anticipated capital and liquidity needs, strategic focus and the
future development of its product candidates, including MAT2203 and
MAT2501, the anticipated timing of regulatory submissions, the
anticipated timing of clinical studies, the anticipated timing of
regulatory interactions, the Company’s ability to identify and
pursue development and partnership opportunities for its products
or platform delivery technology on favorable terms, if at all, and
the ability to obtain required regulatory approval and other
statements that are predictive in nature, that depend upon or refer
to future events or conditions. All statements other than
statements of historical fact are statements that could be
forward-looking statements. Forward-looking statements include
words such as "expects," "anticipates," "intends," "plans,"
"could," "believes," "estimates" and similar expressions. These
statements involve known and unknown risks, uncertainties and other
factors which may cause actual results to be materially different
from any future results expressed or implied by the forward-looking
statements. Forward-looking statements are subject to a number of
risks and uncertainties, including, but not limited to, our ability
to obtain additional capital to meet our liquidity needs on
acceptable terms, or at all, including the additional capital which
will be necessary to complete the clinical trials of our product
candidates; our ability to successfully complete research and
further development and commercialization of our product
candidates; the uncertainties inherent in clinical testing; the
timing, cost and uncertainty of obtaining regulatory approvals; our
ability to protect the Company’s intellectual property; the loss of
any executive officers or key personnel or consultants;
competition; changes in the regulatory landscape or the imposition
of regulations that affect the Company’s products; and the other
factors listed under "Risk Factors" in our filings with the SEC,
including Forms 10-K, 10-Q and 8-K. Investors are cautioned not to
place undue reliance on such forward-looking statements, which
speak only as of the date of this release. Except as may be
required by law, the Company does not undertake any obligation to
release publicly any revisions to such forward-looking statements
to reflect events or circumstances after the date hereof or to
reflect the occurrence of unanticipated events. Matinas BioPharma’s
product candidates are all in a development stage and are not
available for sale or use.
Investor and Media
ContactsPeter
VozzoWestwicke443-213-0505peter.vozzo@westwicke.com
Ian CooneyDirector – Investor Relations &
Corporate DevelopmentMatinas Biopharma, Inc.(415)
722-4563icooney@matinasbiopharma.com
Matinas Biopharma (AMEX:MTNB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Matinas Biopharma (AMEX:MTNB)
Historical Stock Chart
From Apr 2023 to Apr 2024